HK inno.N surpassed 500 billion won in sales for the first time in the first half of this year.
The company noted that the sales for the last first half were provisionally tallied at 510.4 billion won, an increase of 18.2% compared to the previous year. During the same period, operating profit rose by 7.9% to 44.9 billion won.
Sales in the second quarter reached 263.1 billion won, marking a 20% increase over the same period last year, while operating profit fell by 19.8% to 19.5 billion won.
The company explained that although sales increased due to balanced growth in the professional pharmaceuticals (ETC) institutional sector, operating profit declined due to a temporary drop in profit resulting from the recall of beverage products in the H&B (health and beauty) institutional sector.
Sales in the ETC institutional sector for the second quarter were 243.1 billion won, up 25.5% compared to the same period last year. Sales of the new drug for gastroesophageal reflux disease, "K-Cab," reached 49.2 billion won, with domestic sales at 48.1 billion won. This is a 31.6% increase compared to the same period last year. Exports amounted to 1.1 billion won, which is an increase of 108.1% compared to the same period last year. Additionally, sales of intravenous fluids in the second quarter also increased by 16.6% to 33.9 billion won compared to the same period last year.
However, sales in the H&B institutional sector for the second quarter were 20 billion won, a decrease of 21.8% compared to the same period last year. The flagship product, a hangover remedy "Condition," recorded sales of 13.1 billion won, down 20% from the same period last year.